ATGGF OTC

Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system. Its development focuses on addressing Alzheimer's disease, cognitive impairment associated with depression, and the anxiety, sleep, and behavioral challenges seen in fragile X syndrome. Founded in 1999, the company, based in Sydney, Australia, operated as Actinogen Limited until its name change to Actinogen Medical Limited in November 2015.